Revvity, Inc. (NYSE: RVTY) had its price target lowered by analysts at Barclays PLC from $140.00 to $135.00. They now have an "overweight" rating on the stock.
Revvity, Inc. (RVTY)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
RVTY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVTY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVTY alerts
High impacting Revvity, Inc. news events
Weekly update
A roundup of the hottest topics
RVTY
News
- Revvity to Present at J.P. Morgan Healthcare ConferenceBusiness Wire
- Revvity, Inc. (NYSE: RVTY) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating. They now have a $138.00 price target on the stock.MarketBeat
- Revvity Broadens Relationship with Genomics England to Advance Genomics in the UKBusiness Wire
- Revvity to Present at 7th Annual Evercore ISI HealthCONx ConferenceBusiness Wire
- Scale Biosciences and Revvity’s BioLegend Launch First-of-its-Kind Solution for High Parameter Protein Profiling of Single CellsBusiness Wire
RVTY
Earnings
- 11/4/24 - Beat
RVTY
Sec Filings
- 11/19/24 - Form NPORT-P
- 11/14/24 - Form SC
- 11/8/24 - Form SC
- RVTY's page on the SEC website